| Literature DB >> 26286268 |
Huaying Wang1, Xiao Gu1, Yuesong Weng2, Tao Xu1, Zhongming Fu1, Weidong Peng1, Wanjun Yu3.
Abstract
BACKGROUND: Bacterial infection of the lower respiratory tract is believed to play a major role in the pathogenesis of chronic obstructive pulmonary disease (COPD) and acute exacerbations of COPD (AECOPD). This study investigates the potential relationship between AECOPD and the load of six common bacterial pathogens in the lower respiratory tract using real-time quantitative PCR (RT-qPCR) in COPD patients.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26286268 PMCID: PMC4543462 DOI: 10.1186/s12890-015-0094-z
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
RT-qPCR primers and assay performance summary
| Organism | Target gene | Primer/Probe sequences | Assay linearity | Ref. |
|---|---|---|---|---|
|
|
| F:5′-CTTCATATGTGTTAAGTCTTGCAGCTT-3′ | R2 = 0.995 | [ |
| R:5′-TTCACTCGCTTTATTCAATTGTTCTG-3′ | Slope = −3.91 | |||
| P: 5′-6-FAM -ATGTTAAATGGCAATCCT-TAMRA -3′ | Efficiency = 1.04 | |||
|
|
| F: 5′-GATGAAACGACCTGATTGCATTC-3′ | R2 = 0.997 | [ |
| R: 5′-CCGGGCTGTCGGGATAAG-3′ | Slope = −3.60 | |||
| P:5′-6-FAM-CGCGAACTGGAAGGGCCCG-TAMRA-3′ | Efficiency = 1.07 | |||
|
|
| F: 5′-GCTGTTTTAGCAGATAGTGAGATCGA-3′ | R2 = 0.995 | [ |
| R: 5′-TCCCAGTCGGTGCTGTCA-3′ | Slope = −3.11 | |||
| P: 5′-6-FAM-AATGTTACGCAACTGACGAG-TAMRA -3′ | Efficiency = 1.12 | |||
|
|
| F: 5′-GGCGTGGGTGTGGAAGTC-3′ | R2 = 0.995 | [ |
| R: 5′-TGGTGGCGATCTTGAACTTCTT-3′ | Slope = −3.55 | |||
| P: 5′-6-FAM-TGCAGTGGAACGACA-TAMRA-3′ | Efficiency = 0.96 | |||
|
|
| F:5′-CCAGCTGCTAAAGTATTAGTAGAAG-3′ | R2 = 0.997 | [ |
| R: 5′-TTCACCGTAAGATACTGTGCC-3′ | Slope = −4.22 | |||
| P: 5′-6-FAM -CAGATGCAGTTGAAGGTTATTTAG- | Efficiency = 0.95 | |||
| TAMRA-3′ | ||||
|
|
| F: 5′-GTGAGTGCCGCTTTACAACC-3′ | R2 = 0.998 | [ |
| R: 5′-TGTATCGCCTGCCAAGACAA-3′ | Slope = −3.66 | |||
| P:5′-6-FAM-TGCTTTTGCAGCTGTTAGCCAGCCTAA- | Efficiency = 0.91 | |||
| TAMRA-3′ |
Optimized conditions for egc, khe, cps, gyrB, omp P6 and copB RT-qPCR assay
| Reaction | Final concentration | |||||
|---|---|---|---|---|---|---|
| Components |
|
|
|
|
|
|
| TaqMan Universal PCR Mastermix | 1× | 1× | 1× | 1× | 1× | 1× |
| Primer | 0.6 μmol/L | 0.6 μmol/L | 0.6 μmol/L | 0.6 μmol/L | 0.6 μmol/L | 0.6 μmol/L |
| Probe | 0.3 μmol/L | 0.3 μmol/L | 0.3 μmol/L | 0.3 μmol/L | 0.3 μmol/L | 0.3 μmol/L |
| Total volume | 20 μl | 20 μl | 20 μl | 20 μl | 20 μl | 20 μl |
| Melt | 95 °C, 10 min | 94 °C, 4 min | 94 °C, 4 min | 95 °C, 10 min | 94 °C, 4 min | 94 °C, 4 min |
| Denaturation | 95 °C, 15 s | 94 °C, 30 s | 94 °C, 30 s | 95 °C, 15 s | 94 °C, 30 s | 94 °C, 30 s |
| Annealing/Extension | 60 °C, 60 s | 60 °C, 60 s | 60 °C, 60 s | 60 °C, 60 s | 60 °C, 60 s | 60 °C, 60 s |
| Cycles | 45 | 40 | 40 | 45 | 40 | 40 |
| PCR Product Size | 82 base pairs | 77 base pairs | 67 base pairs | 190 base pairs | 156 base pairs | 71base pairs |
Demographic and clinical characteristics of patients in the HS, stable COPD and AECOPD groups
| HS | Stable COPD patients | AECOPD patients | |
|---|---|---|---|
| ( | ( | ( | |
| Age (years) | 65 ± 8 | 67 ± 7 | 69 ± 6 |
| Gender (M/F) | 20/13 | 28/6 | 27/5 |
| BMI (kg/m2) | 23.1 ± 5.1 | 24.2 ± 4.9 | 23.8 ± 3.9 |
| Tobacco (pack/year) | - | 44.2 ± 25.6 | 43.7 ± 27.8 |
| FEV1 (L) | 3.3 ± 0.3 | 1.3 ± 0.1** | 1.2 ± 0.2** |
| FEV1 % predicted | 103.6 ± 7.3 | 53.4 ± 8.8** | 51.4 ± 9.0** |
| FVC (L) | 4.0 ± 0.2 | 2.9 ± 0.2* | 2.7 ± 0.2* |
| FVC % predicted | 102.7 ± 6.7 | 81.4 ± 9.3** | 79.9 ± 7.4** |
| FEV1/FVC (%) | 82.3 ± 6.1 | 43.8 ± 4.4** | 44.1 ± 7.1** |
| WBC (x109/L) | 5.6 ± 1.2 | 6.1 ± 1.7 | 11.4 ± 5.1**## |
| Neutrophils (%) | 64.6 ± 6.7 | 68.7 ± 7.6* | 85.4 ± 6.1**## |
| CRP (mg/L) | 6.7 ± 2.4 | 16.1 ± 6.7** | 85.2 ± 30.4**## |
All data are expressed as means ± SEM, except gender. * P < 0.05 and ** P < 0.01 vs. the HS group; # P < 0.05 and ## P < 0.01 vs. the stable COPD group; FEV1, Forced expiratory volume in one second; FVC, forced vital capacity; CRP, C-reactive protein; HS, Healthy subjects. The spirometry data in AECOPD patients reflect the baseline data in the stable stage
Microbiological culture results of PSB and BALF samples obtained from patients in the HS, stable COPD and AECOPD groups
|
| HS | Stable COPD patients | AECOPD patients | |||
|---|---|---|---|---|---|---|
| ( | ( | ( | ||||
| PSB | BALF | PSB | BALF | PSB | BALF | |
|
| 29 (87.9) | 29 (87.9) | 20 (58.8) | 15 (44.1) | 9 (28.1) | 8 (25.0) |
|
| 1 (3.0) | 1 (3.0) | 2 (5.9) | 4 (11.8) | 3 (9.4) | 3 (9.4) |
|
| 1 (3.0) | 1 (3.0) | 1 (2.9) | 3 (8.8) | 4 (12.5) | 4 (12.5) |
|
| 2 (6.0) | 2 (6.0) | 4 (11.8) | 5 (14.7) | 3 (9.4) | 4 (12.5) |
|
| 0 | 0 | 2 (5.9) | 2 (2.9) | 4 (12.5) | 5 (15.6) |
|
| 0 | 0 | 2 (5.9) | 3 (8.8) | 6 (18.8) | 5 (15.6) |
|
| 0 | 0 | 1 (2.9) | 2 (2.9) | 2 (6.3) | 2 (6.3) |
|
| 0 | 0 | 1 (2.9) | 2 (2.9) | 1 (3.1) | 1 (3.1) |
aOther isolated bacteria including Acinetobacter baumanii, Escherichia coli, and Streptococcus hemolyticus. HS, Healthy subjects
RT-qPCR analysis of PSB and BALF samples obtained from patients in the HS, stable COPD and AECOPD groups
|
| HS | Stable COPD patients | AECOPD patients | |||
|---|---|---|---|---|---|---|
| ( | ( | ( | ||||
| PSB | BALF | PSB | BALF | PSB | BALF | |
|
| 3 (9.1) | 2 (6.1) | 16 (47.1) | 17 (50.0) | 22 (68.8) | 20 (62.5) |
|
| 5 (15.2) | 6 (18.2) | 10 (29.4) | 9 (26.5) | 15 (46.9) | 16 (50.0) |
|
| 10 (30.3) | 8 (24.2) | 20 (58.8) | 18 (52.9) | 14 (42.8) | 17 (53.1) |
|
| 2 (6.1) | 2 (6.1) | 15 (44.1) | 17 (50.0) | 20 (62.5) | 23 (71.9) |
|
| 5 (15.2) | 6 (18.2) | 18 (52.9) | 20 (58.8) | 25 (78.1) | 24 (75.0) |
|
| 4 (12.1) | 4 (12.1) | 22 (64.7) | 20 (58.8) | 16 (50.0) | 15 (46.9) |
HS, Healthy subjects
Fig. 1Standard curves for Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Pseudomonos aeruginosa, Haemophilus influenzeae, and Moraxella catarrhalis assays. Mean threshold cycle (CT) value ± SEM of three replicates (three per run) for each reaction is shown in relation to the log of CFU calculated per 20 μl of reaction mixture. Relative correlation coefficient (R ) and linear regression equations are reported in the legend
Fig. 2Bacterial load in PSB and BALF samples obtained from COPD patients and healthy subjects. The burden of Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonos aeruginosa, Haemophilus influenzeae, and Moraxella catarrhalis in PSB samples (a), and of Klebsiella pneumoniae, Pseudomonos aeruginosa, Haemophilus influenzeae, and Moraxella catarrhalis in BALF samples (b) obtained from AECOPD patients compared with stable COPD patients. All data are expressed as means ± SEM. * P < 0.05 and ** P < 0.01 vs. the HS group; # P < 0.05 and ## P < 0.01 vs. the stable COPD group
Fig. 3Infiltration of inflammatory cells in airways of COPD patients. The number of total inflammatory cells including neutrophils, lymphocytes, and macrophages in BALF samples obtained from patients in the HS, stable COPD and AECOPD groups were determined (a). The percentage of each cell type from total cells (b). Data are expressed as means ± SEM (n = 20 per group). * P < 0.05 and ** P < 0.01 vs. the HS group; # P < 0.05 and ## P < 0.01 vs. the stable COPD group
Cytokine levels in BALF supernatants obtained from patients in the HS, stable COPD and AECOPD groups
| Cytokines (pg/ml) | HS | Stable COPD patients | AECOPD patients |
|---|---|---|---|
| ( | ( | ( | |
| IL-1β | 0.15 ± 0.05 | 0.21 ± 0.07** | 0.58 ± 0.13**## |
| IL-6 | 0.64 ± 0.15 | 1.05 ± 0.21** | 2.07 ± 0.22**## |
| IL-8 | 6.81 ± 1.59 | 9.50 ± 1.3** | 31.39 ± 6.02**## |
| IL-10 | 0.10 ± 0.06 | 0.18 ± 0.06** | 0.30 ± 0.10**## |
| TNF-α | 0.02 ± 0.01 | 0.05 ± 0.01** | 0.27 ± 0.11**## |
All data are expressed as means ± SEM. * P < 0.05 and ** P < 0.01 vs. the HS group; # P < 0.05 and ## P < 0.01 vs. the stable COPD group. HS, Healthy subjects
Correlation analysis of bacterial burden and inflammatory index in BALF samples
|
|
|
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (log CFU/ml) | (log CFU/ml) | (log CFU/ml) | (log CFU/ml) | (log CFU/ml) | (log CFU/ml) | |||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Neutrophil (%) | 0.175 | 0.252 | 0.458 | 0.002 | 0.071 | 0.641 | 0.497 | 0.003 | 0.564 | <0.01 | 0.551 | <0.01 |
| IL-1β (pg/ml) | −0.082 | 0.511 | 0.327 | 0.010 | 0.086 | 0.479 | 0.452 | 0.001 | 0.682 | <0.01 | 0.503 | <0.01 |
| IL-6 (pg/ml) | 0.068 | 0.589 | 0.317 | 0.012 | 0.082 | 0.500 | 0.413 | 0.004 | 0.663 | <0.01 | 0.549 | <0.01 |
| IL-8 (pg/ml) | 0.165 | 0.187 | 0.314 | 0.013 | 0.044 | 0.720 | 0.341 | 0.018 | 0.694 | <0.01 | 0.587 | <0.01 |
| IL-10 (pg/ml) | −0.042 | 0.738 | 0.201 | 0.118 | 0.110 | 0.364 | 0.205 | 0.163 | 0.451 | <0.01 | 0.376 | 0.003 |
| TNF- α (pg/ml) | 0.266 | 0.031 | 0.249 | 0.051 | 0.121 | 0.316 | 0.320 | 0.027 | 0.703 | <0.01 | 0.493 | <0.01 |
Correlation analysis of bacterial burden in PSB samples and pulmonary function
|
|
|
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (log CFU/ml) | (log CFU/ml) | (log CFU/ml) | (log CFU/ml) | (log CFU/ml) | (log CFU/ml) | |||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |
| FEV1 % predicted | −0.674 | <0.01 | −0.865 | <0.01 | −0.543 | <0.01 | −0.664 | <0.01 | −0.849 | <0.01 | −0.813 | <0.01 |
| FVC % predicted | −0.597 | <0.01 | −0.756 | <0.01 | −0.419 | <0.01 | −0.586 | <0.01 | −0.728 | <0.01 | −0.675 | <0.01 |
| FEV1/FVC | −0.660 | <0.01 | −0.833 | <0.01 | −0.532 | <0.01 | −0.639 | <0.01 | −0.814 | <0.01 | −0.776 | <0.01 |